(PBH) Prestige Brand Holdings - Ratings and Ratios
Pain Powders, Diaper Rash Cream, Sore Throat Sprays, Eye Drops, Wart Removers
PBH EPS (Earnings per Share)
PBH Revenue
Description: PBH Prestige Brand Holdings
Prestige Consumer Healthcare Inc. (NYSE:PBH) is a leading developer, manufacturer, and distributor of over-the-counter (OTC) health and personal care products. The companys diverse portfolio includes well-known brands such as BC, Goodys, Chloraseptic, Clear Eyes, Compound W, and Monistat, among others. With a presence in North America, Australia, and internationally, PBH operates through two segments: North American OTC Healthcare and International OTC Healthcare.
From a business perspective, PBHs products cater to various consumer needs, including pain relief, skin care, eye care, and feminine hygiene. The companys products are sold through multiple channels, including mass merchandisers, drug stores, e-commerce platforms, and other retail outlets. Key performance indicators (KPIs) to monitor PBHs performance include revenue growth, gross margin expansion, and operating cash flow generation. Notably, the companys ability to maintain its market share in a competitive OTC healthcare landscape is crucial.
To further evaluate PBHs prospects, its essential to analyze its financial metrics. With a market capitalization of approximately $3.785 billion, PBHs price-to-earnings (P/E) ratio stands at 17.92, indicating a relatively stable valuation. The companys return on equity (RoE) of 12.20% suggests a decent level of profitability. Additionally, monitoring PBHs dividend yield, payout ratio, and debt-to-equity ratio can provide insights into its financial health and ability to return value to shareholders.
From a growth perspective, PBHs ability to expand its product portfolio through strategic acquisitions and innovation is vital. The companys history of acquiring and integrating various brands, such as the recent acquisition of certain assets from Pfizer, demonstrates its ability to drive growth through M&A. Furthermore, PBHs investment in research and development (R&D) and marketing efforts will be crucial in maintaining its competitive edge and driving future growth.
PBH Stock Overview
| Market Cap in USD | 3,293m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2005-02-10 |
PBH Stock Ratings
| Growth Rating | 27.6% |
| Fundamental | 66.5% |
| Dividend Rating | 0.21% |
| Return 12m vs S&P 500 | -27.8% |
| Analyst Rating | 3.71 of 5 |
PBH Dividends
Currently no dividends paidPBH Growth Ratios
| Growth Correlation 3m | -91.3% |
| Growth Correlation 12m | -2.8% |
| Growth Correlation 5y | 89.5% |
| CAGR 5y | 7.55% |
| CAGR/Max DD 3y | 0.26 |
| CAGR/Mean DD 3y | 0.96 |
| Sharpe Ratio 12m | -0.42 |
| Alpha | 0.00 |
| Beta | 0.085 |
| Volatility | 23.57% |
| Current Volume | 634.5k |
| Average Volume 20d | 600.6k |
| Stop Loss | 61.3 (-3%) |
| Signal | 0.31 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (213.0m TTM) > 0 and > 6% of Revenue (6% = 67.2m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 0.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 33.11% (prev 22.87%; Δ 10.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 275.8m > Net Income 213.0m (YES >=105%, WARN >=100%) |
| Net Debt (903.2m) to EBITDA (359.6m) ratio: 2.51 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.8m) change vs 12m ago -0.86% (target <= -2.0% for YES) |
| Gross Margin 56.18% (prev 54.30%; Δ 1.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.24% (prev 33.66%; Δ -0.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.43 (EBITDA TTM 359.6m / Interest Expense TTM 44.7m) >= 6 (WARN >= 3) |
Altman Z'' 3.94
| (A) 0.11 = (Total Current Assets 480.5m - Total Current Liabilities 109.7m) / Total Assets 3.43b |
| (B) 0.47 = Retained Earnings (Balance) 1.60b / Total Assets 3.43b |
| (C) 0.10 = EBIT TTM 332.3m / Avg Total Assets 3.37b |
| (D) 1.00 = Book Value of Equity 1.57b / Total Liabilities 1.58b |
| Total Rating: 3.94 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.51
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 6.45% = 3.22 |
| 3. FCF Margin 23.91% = 5.98 |
| 4. Debt/Equity 0.54 = 2.36 |
| 5. Debt/Ebitda 2.78 = -1.44 |
| 6. ROIC - WACC (= 3.90)% = 4.87 |
| 7. RoE 11.82% = 0.98 |
| 8. Rev. Trend -27.77% = -2.08 |
| 9. EPS Trend 32.50% = 1.63 |
What is the price of PBH shares?
Over the past week, the price has changed by -4.26%, over one month by -2.57%, over three months by -24.45% and over the past year by -14.22%.
Is Prestige Brand Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PBH is around 55.65 USD . This means that PBH is currently overvalued and has a potential downside of -11.95%.
Is PBH a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 3
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the PBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 82.8 | 31% |
| Analysts Target Price | 82.8 | 31% |
| ValueRay Target Price | 60 | -5.1% |
Last update: 2025-09-04 04:45
PBH Fundamental Data Overview
CCE Cash And Equivalents = 139.5m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 15.7066
P/E Forward = 14.6413
P/S = 2.9397
P/B = 1.7638
P/EG = 2.5698
Beta = 0.436
Revenue TTM = 1.12b USD
EBIT TTM = 332.3m USD
EBITDA TTM = 359.6m USD
Long Term Debt = 992.7m USD (from longTermDebt, last quarter)
Short Term Debt = 8.60m USD (from shortTermDebt, last quarter)
Debt = 1.00b USD (Calculated: Short Term 8.60m + Long Term 992.7m)
Net Debt = 903.2m USD (from netDebt column, last quarter)
Enterprise Value = 4.15b USD (3.29b + Debt 1.00b - CCE 139.5m)
Interest Coverage Ratio = 7.43 (Ebit TTM 332.3m / Interest Expense TTM 44.7m)
FCF Yield = 6.45% (FCF TTM 267.8m / Enterprise Value 4.15b)
FCF Margin = 23.91% (FCF TTM 267.8m / Revenue TTM 1.12b)
Net Margin = 19.02% (Net Income TTM 213.0m / Revenue TTM 1.12b)
Gross Margin = 56.18% ((Revenue TTM 1.12b - Cost of Revenue TTM 490.9m) / Revenue TTM)
Tobins Q-Ratio = 2.64 (Enterprise Value 4.15b / Book Value Of Equity 1.57b)
Interest Expense / Debt = 1.02% (Interest Expense 10.2m / Debt 1.00b)
Taxrate = 24.49% (69.6m / 284.2m)
NOPAT = 250.9m (EBIT 332.3m * (1 - 24.49%))
Current Ratio = 4.38 (Total Current Assets 480.5m / Total Current Liabilities 109.7m)
Debt / Equity = 0.54 (Debt 1.00b / last Quarter total Stockholder Equity 1.86b)
Debt / EBITDA = 2.78 (Net Debt 903.2m / EBITDA 359.6m)
Debt / FCF = 3.74 (Debt 1.00b / FCF TTM 267.8m)
Total Stockholder Equity = 1.80b (last 4 quarters mean)
RoA = 6.21% (Net Income 213.0m, Total Assets 3.43b )
RoE = 11.82% (Net Income TTM 213.0m / Total Stockholder Equity 1.80b)
RoCE = 11.89% (Ebit 332.3m / (Equity 1.80b + L.T.Debt 992.7m))
RoIC = 8.93% (NOPAT 250.9m / Invested Capital 2.81b)
WACC = 5.03% (E(3.29b)/V(4.29b) * Re(6.33%)) + (D(1.00b)/V(4.29b) * Rd(1.02%) * (1-Tc(0.24)))
Shares Correlation 3-Years: -30.30 | Cagr: -0.08%
Discount Rate = 6.33% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.86% ; FCFE base≈259.3m ; Y1≈269.7m ; Y5≈309.7m
Fair Price DCF = 110.5 (DCF Value 5.44b / Shares Outstanding 49.2m; 5y FCF grow 4.24% → 3.0% )
EPS Correlation: 32.50 | EPS CAGR: -2.55% | SUE: -0.57 | # QB: 0
Revenue Correlation: -27.77 | Revenue CAGR: -5.23% | SUE: N/A | # QB: None
Additional Sources for PBH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle